HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales

MT Newswires Live10-31

HUTCHMED (HCM) said Thursday it earned a $20 million milestone payment from Takeda (TAK) triggered by reaching over $200 million in sales of metastatic colorectal cancer treatment fruquintinib.

Takeda, who holds exclusive global rights to the drug outside of mainland China, Hong Kong and Macau, generated $203 million in net sales of fruquintinib in nine months ended September 2024, the comany said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment